Anemia

CMV in Kidney Disease Linked with Anemia

CMV in Kidney Disease Linked with Anemia

Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.

Renal Stenting and the CORAL Study: Interview with Lance Dworkin, MD

Renal Stenting and the CORAL Study: Interview with Lance Dworkin, MD

By

CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.

ESA Resistance Found To Increase Mortality

By

Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.

MI-Acquired Anemia Rates Vary by Hospital

MI-Acquired Anemia Rates Vary by Hospital

Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.

Ribavirin May Treat HEV Infection in Transplant Recipients

Ribavirin May Treat HEV Infection in Transplant Recipients

By

Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.

IV Iron Drugs Demonstrate Similar Efficacy, AE Rates

By

Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.

Low Iron Tied to Higher Stroke Risk

Low Iron Tied to Higher Stroke Risk

Platelets may aggregate more easily in iron-deficient patients.

Novel Iron Compound Patented in Japan

Novel Iron Compound Patented in Japan

By

Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.

Guidelines and the Older Patient with CKD

Guidelines and the Older Patient with CKD

By By

Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.

IV Iron Drugs Demonstrate Similar Efficacy, Safety in CKD Patients

IV Iron Drugs Demonstrate Similar Efficacy, Safety in CKD Patients

By

In a study, ferumoxytol and iron sucrose treatment was associated with comparable increases in hemoglobin levels and adverse event rates.

Sickle Cell Trait May Raise Need for Anemia Meds in Dialysis Patients

Sickle Cell Trait May Raise Need for Anemia Meds in Dialysis Patients

By

This trait in African-American hemodialysis patients was associated with a 13.2% higher dose of erythropoiesis-stimulating agents.

Iron Status Affects Platelet Counts in Hemodialysis Patients

By

Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.

Anemic Peritoneal Dialysis Patients May Benefit from Folic Acid

By

Folic acid treatment significantly improved hemoglobin levels and decreased epoetin alfa use.

Phosphate Binder Found to Cut IV Iron, ESA Use

By

Elemental iron requirement was reduced by half in patients receiving ferric citrate versus an active control.

Changes in U.S. Anemia Management Not Seen in Europe, Japan

By

These include use of lower ESA doses and hemoglobin levels.

Intradialytic Exercise May Improve Renal Anemia in the Elderly

By

Weekly dose of erythropoiesis-stimulating agents decreased and hemoglobin levels increased.

Low Hemoglobin Hikes Mortality in Pediatric Dialysis Patients

By

Patients with levels below 10 g/dL had the highest unadjusted mortality and all-cause hospitalization rates.

Low TSAT Predicts Worse Outcomes in Anemic Dialysis Patients

By

A transferrin saturation of 20% or less was associated with a 2.2 times increased risk of death from any cause.

ESA Use Declining at Hospital-Based Dialysis Centers

By

Study also documents use of higher IV iron doses and declining hemoglobin levels.

Erythropoietin Resistance Linked to Low Vitamin C

By

Plasma ascorbic acid levels in the physiologic range correlated inversely with EPO resistance.

Investigational Iron Drug Safe, Effective in Hemodialysis Patients

By

Soluble ferric pyrophosphate is a unique carbohydrate-free formulation administrated via dialysate.

Some Anemic Kids on Dialysis Are at Higher Death Risk

By

Children on dialysis who have anemia and require high doses of drugs to treat it are at increased risk of dying prematurely.

Advantages Cited with Novel Iron Drug

By

Soluble ferric pyrophosphate significantly decreased ESA use while maintaining target hemoglobin levels without increasing iron stores.

Transfusions On the Rise in Dialysis Patients

By

The trend is most pronounced among Medicare recipients since the debut of bundling, ESA labeling changes.

Hemoglobin Levels Decline After ESA Label Changes

By

Study also showed an increase in the proportion of patients with hemoglobin level below 10 g/dL and in transfusion rates.

FDA: Omontys Injection Pulled From Market

FDA: Omontys Injection Pulled From Market

Voluntary recall of anemia drug due to reports of anaphylaxis, including three deaths

Preoperative ESR Predicts Kidney Cancer Survival After Nephrectomy

By

Preoperative anemia associated with elevated risk of deaths from other illnesses.

Study: IV Iron Use Less with Once-Monthly ESA

By

Once-monthly injections of peginesatide are as effective as one to three injections per week of epoetin in maintaining hemoglobin levels.

IV Iron Repletion in 15 Minutes, Researchers Report

By

No major adverse events reported with administering 1.02 grams of ferumoxytol in patients with iron deficiency anemia.

ESAs Boost Stroke Risk, But Not Mortality

By

Meta-analysis also reveals an increased risk of vascular access thrombosis, but no increased likelihood of end-stage renal disease.

Sign Up for Free e-newsletters